Publishing: September 2021 | Report Code: LS10178 | Available Format: PDF
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.
North America leads the hospital infection therapeutics market followed by Europe. The North America hospital infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital infections and high demands of therapeutic drugs in the emerging countries such India and China.
Hospital acquired infections are caused produced by viral pathogens, fungal and bacterial. Most of the hospital infections crop up from intensive care units. Varied range of hospital infections are being treated by various antimicrobial drugs. The patients staying in the hospitals develop several infections during their treatment. . The infections are known as hospital-acquired infections or hospital infections. The hospital acquired infections spread in the hospitals, rehabilitation centers, outpatient surgery centers, nursing homes and dialysis centers.
Some of the pipeline drugs available in the market for hospital acquired infections are MK-3415A, Amikacin Inhale, Oritavancin, Surotomycin, Ceftolozane, Dalvance, Plazomicin, Eravacycline, Tedizolid, Delafloxacin, and CAZ AVI. In 2011, according to the centers for disease control and prevention, around 1.6 million hospital acquired infections have been reported from all types of bacteria in US every year. Additionally, in 2013 about 4 million patients were identified with hospital acquired infections in Europe.
Lack of skilled nursing staff in underdeveloped and developing economies is increasing the incidences of hospital-acquired infections, which in turn is driving the growth of hospital infection therapeutics market. The increasing number of multi drug resistant bacterial strains are presently making antibacterial drugs obsolete available. Also the increasing hospital surveillance and infection control programs in developed countries has lead to a decline in number of hospital infections. All these factors are responsible for restraining the growth of hospital infection therapeutics market.
The hospital infection therapeutics market can be categorized on the basis of drug type into, antifungal drugs, antibacterial drugs and antiviral drugs. Antibacterial drug leads the global hospital infection therapeutics market and is also expected to grow at the highest rate in coming years among the drug types in hospital infection therapeutics market.
On the basis of infection types, the hospital infection therapeutics market can be categorized into hospital acquired pneumonia, urinary tract infections, bloodstream infections, surgical site infections and gastrointestinal disorders. Hospital acquired pneumonia leads the global hospital infection therapeutics market, under the types of infection categories. While urinary tract infections are expected to grow at an exponential rate in the coming years.
Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws